Abstraet--Gene transfer is an exciting new tool in medical therapy and scientific investigation, but only very recently has it begun to be developed in the auditory system. This paper describes in vivo and ex vivo experiments using an adenoviral vector (Ad. RSVntlacZ), which is a replication-deficient virus based on a human adenoviral (serotype 5) genomic backbone. The in vivo experiments demonstrate successful gene transfer into multiple types of cochlear cells. We observed a relatively efficient transduction, several weeks of sustained transgene expression and an absence of major lethal cytotoxicity in spiral ganglion and epithelial cells of the cochlea in adult animals. The ex vivo experiments were performed using fibroblasts transduced in vitro with Ad. RSVntlacZ. Two weeks after inoculation of the fibroblasts into the perilymph, we observed transplanted fibroblasts, which were adherent to the lining of the perilymphatic spaces, and were expressing the lacZ transgene. We speculate that, as the genetic basis of degenerative cochlear diseases is characterized on a mutational level, transgene expression will allow us to test hypotheses regarding the effects of specific genes on cochlear cell biology. Gene transfer will not only increase our understanding of the pathophysiology of hearing loss, but also may provide gene therapy for disease. © 1997 ISDN
Gene transfer is a powerful technique for altering gene expression in cells and tissues, and the cochlea is potentially a suitable organ for experimental and therapeutic gene transfer. By nature of its structural design, the cochlea possesses several advantages as an end-organ for gene transfer. First, there are several cell types in the cochlea that can be quantified rather precisely. Second, although it is encased in the temporal bone and relatively isolated, inoculation with genetic vectors technically is feasible. Third, the enclosed fluid spaces (the scala tympani and scala vestibuli, which contain perilymph, and the scala media, which contains endolymph) enable diffusible particles, such as viruses or proteins, to disperse rapidly throughout the cochlea. Various agents have been introduced experimentally into the perilymph by injection through the round window membrane, and osmotic pumps have been used to deliver a continuous infusion 3 into the scala tympani and obtain therapeutic levels of growth factors in the ear. 25' 26
In vivo gene transfer involves inoculation of the target organ with a vector containing a transgenic insert.17 In v ivo gene transfer in the cochlea achieves transduction of cochlear cells and the transgenic protein produced may exert an effect intracellularly, or if secreted, may diffuse throughout the perilymph and act upon other populations of cochlear cells. In order to introduce genes into any of the quiescent cells of the inner ear (hair cells, supporting cells of the organ of Corti and spiral ganglion cells), in vivo gene transfer is currently the only available technique. In contrast, ex vivo gene transfer typically involves transduction of host cells (such as dermal fibroblasts) in culture, followed by injection of the transduced cells into the cochlea. Ex vivo gene transfer in the cochlea has been demonstrated recently using cultures of neonatal cochlear explants. 7 Ex vivo gene therapy has two advantages. First, in contrast to in vivo gene transfer in which any cochlear cells potentially may be infected with the virus, ex vivo gene therapy utilizes a preselected host cell population. Second, because a large number of cells may be transduced, a larger dose of transgene potentially may be introduced into the cochlea. The applicability of ex vivo gene therapy is, however, limited to genes that encode diffusible, secreted proteins.
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